Claret Medical has raised $21.2 million in a new round of equity financing, according to an SEC filing posted last week.
In a press release posted today, the company said that it raised $14.5 million in a Series C round led by Lightstone Ventures and joined by Easton Capital, HealthCor Partners, Incept and Sante Ventures.
Proceeds are slated to support market access program, next-gen R&D and expanding commercialization to support its Sentinel cerebral protection system.
The Sentinel embolic protection device is designed to trap blood clots and prevent stroke during heart valve replacement procedures, which Claret Medical touts as the 1st and only FDA-cleared device to do so.
“We appreciate our investors’ continued confidence in the large market opportunity presented by our technology. Our ongoing investment in a broad clinical program has shown that Sentinel is safe, easy to use and highly effective in reducing periprocedural TAVR stroke by 70 percent.1 We look forward to continuing to work with leading TAVR centers around the country to integrate Protected TAVR using the Sentinel into their programs to enhance patient safety,” Claret Medical CEO Azin Parhizgar said in a press release.
Money in the SEC-filing related funding round came from 35 anonymous investors, according to the filing, with the 1st sale noted on June 22.
Earlier this week, Claret Medical released results from a study of its Sentinel cerebral protection system, touting reduced early occurrence of stroke associated with transcatheter aortic valve replacement procedures and lowered mortality rates.
The study of the device was recently published in the Journal of the American College of Cardiology: Cardiovascular Interventions, the company said.